1,372 reports of this reaction
3.1% of all AFLIBERCEPT reports
#5 most reported adverse reaction
ENDOPHTHALMITIS is the #5 most commonly reported adverse reaction for AFLIBERCEPT, manufactured by Regeneron Pharmaceuticals, Inc.. There are 1,372 FDA adverse event reports linking AFLIBERCEPT to ENDOPHTHALMITIS. This represents approximately 3.1% of all 43,844 adverse event reports for this drug.
Patients taking AFLIBERCEPT who experience endophthalmitis should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
ENDOPHTHALMITIS is moderately reported among AFLIBERCEPT users, representing a notable but not dominant share of adverse events.
In addition to endophthalmitis, the following adverse reactions have been reported for AFLIBERCEPT:
The following drugs have also been linked to endophthalmitis in FDA adverse event reports:
ENDOPHTHALMITIS has been reported as an adverse event in 1,372 FDA reports for AFLIBERCEPT. This does not prove causation, but indicates an association observed in post-market surveillance data.
ENDOPHTHALMITIS accounts for approximately 3.1% of all adverse event reports for AFLIBERCEPT, making it a notable side effect.
If you experience endophthalmitis while taking AFLIBERCEPT, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.